Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15499585

How consistent are expression chip platforms?

Bertrand R Jordan
View original source ↗Export metadata ↓

Abstract

DNA arrays are now widely used in academia and industry, and expression profiling is recognised as a major tool for basic research as well as for drug development. It is also likely, in the near future, that DNA arrays will be used in clinical laboratories for diagnostic and prognostic purposes. Since several types of arrays are being used, the coherence of results obtained using these diverse platforms becomes an important issue: to what extent can data obtained in different laboratories and with different equipment be combined? Several recent papers address this issue and demonstrate that the expected agreement is not necessarily found. Consistent results can be obtained, but this requires careful identification of the genes assessed by the arrays, and scrupulous adherence to strict experimental procedures.

Explore related subjects

DNA, ComplementaryOligonucleotide Array Sequence AnalysisRNA, MessengerReproducibility of ResultsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bertrand R Jordan. 2004. How consistent are expression chip platforms?. https://doi.org/10.1002/bies.20128

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

High-resolution cDNA microarray-based comparative genomic hybridization analysis in neuroblastoma.

Neuroblastoma (NB) is one of the most common pediatric solid tumors and displays a broad variety of genomic alterations. Array-based comparative genomic hybridization (A-CGH) is a novel technology enabling the high-resolution detection of DNA copy number aberrations. In this article, we outline features of this new technology and approaches of data analysis. We focus on stage specific DNA copy number variations in neuroblastoma detected by cDNA array-based comparative genomic hybridization (A-CGH). We also discuss hypothetic evolutionary models of neuroblastoma progression that can be derived from A-CGH data.

DNA, Complementary↗
PubMed2005

A review of DNA microarray analysis of human neuroblastomas.

Neuroblastoma (NBL) is an enigmatic tumor with heterogeneous clinical behaviors including maturation, regression, and aggressive growth. Despite recent progress in therapeutic strategies against advanced NBL, long-term outcomes still remain very poor. The prediction of cancer prognosis is one of the most urgent demands to initiate the suitable treatment of NBL. Recent papers have demonstrated that cancers can be diagnosed on the basis of gene expression profiling. We have been proceeded NBL cDNA project to collect a large number of genes expressed in NBLs, to identify the genes differentially expressed between favorable and unfavorable NBLs, and to make an NBL-proper cDNA chip for large-scale analysis of NBL tumors. Computational analysis of gene expression data in NBLs identified many prognosis-related genes and provided a classifier to predict the patient prognosis with high efficiency. Conversion of these findings into better diagnosis and treatment is now underway. Thus, molecular profiling of NBL has become a feasible tool for clinical applications.

DNA, Complementary↗
PubMed2005

cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures.

Microarray technology has become a standard tool for generation of gene expression profiles to explore human disease processes. Being able to start from minute amounts of RNA extends the fields of application to core needle biopsies, laser capture microdissected cells, and flow-sorted cells. Several RNA amplification methods have been developed, but no extensive comparability and concordance studies of gene expression profiles are available. Different amplification methods may produce differences in gene expression patterns. Therefore, we compared profiles processed by a standard microarray protocol with three different types of RNA amplification: (i) two rounds of linear target amplification, (ii) random amplification, and (iii) amplification based on a template switching mechanism. The latter two methods accomplish target amplification in a nonlinear way using PCR technology. Starting from as little as 50 ng of total RNA, the yield of labeled cRNA was sufficient for hybridization to Affymetrix HG-U133A GeneChip array using the respective methods. Replicate experiments were highly reproducible for each method. In comparison with the standard protocol, all three approaches are less sensitive and introduced a minor but clearly detectable bias of the detection call. In conclusion, the three amplification protocols used are applicable for GeneChip analysis of small tissue samples.

DNA, Complementary↗